Insider Selling: Immunovant (NASDAQ:IMVT) Director Sells 6,000 Shares of Stock

May 21, 2026 by InsiderTrades.com

Key Points

Immunovant director Atul Pande sold 6,000 shares on May 20 at an average price of $32.00, totaling $192,000. The sale reduced his stake by 4.89%, though it was made under a pre-arranged Rule 10b5-1 trading plan.
The company recently missed quarterly earnings expectations, reporting a loss of $0.73 per share versus the $0.60 consensus estimate. Despite the miss, analysts still see major focus on the company’s clinical progress.
Investor attention remains on Immunovant’s pipeline and cash position, including positive rheumatoid arthritis data, a fully enrolled cutaneous lupus trial, and about $902 million in cash to support development of IMVT-1402.

Immunovant, Inc. (NASDAQ:IMVT - Get Free Report) Director Atul Pande sold 6,000 shares of the firm's stock in a transaction dated Wednesday, May 20th. The stock was sold at an average price of $32.00, for a total value of $192,000.00. Following the transaction, the director directly owned 116,731 shares in the company, valued at approximately $3,735,392. The trade was a 4.89% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Immunovant Stock Performance

Shares of IMVT stock opened at $35.56 on Thursday. The stock's 50-day moving average is $26.48 and its two-hundred day moving average is $25.78. The firm has a market cap of $7.24 billion, a price-to-earnings ratio of -13.22 and a beta of 0.70. Immunovant, Inc. has a 1 year low of $13.79 and a 1 year high of $36.29.

Immunovant (NASDAQ:IMVT - Get Free Report) last issued its quarterly earnings data on Wednesday, May 20th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.13). During the same period in the prior year, the firm earned ($0.64) earnings per share. As a group, research analysts predict that Immunovant, Inc. will post -2.67 EPS for the current year.

More Immunovant News

Here are the key news stories impacting Immunovant this week:

Positive Sentiment: Immunovant reported strong Week 16 results from its rheumatoid arthritis study of IMVT-1402, with encouraging response rates that investors viewed as clinically meaningful and supportive of the drug’s potential. Article Title
Positive Sentiment: The company said its cutaneous lupus proof-of-concept trial is fully enrolled and expects topline data in the second half of 2026, giving investors another near-term catalyst. Article Title
Positive Sentiment: Immunovant also highlighted a cash position of about $902 million as of March 31, which should help fund development and support the path toward a possible commercial launch of IMVT-1402 in Graves’ disease. Article Title
Neutral Sentiment: Quarterly results were weaker than expected, with a loss of $0.73 per share versus the $0.60 estimate, but the earnings miss was largely overshadowed by the clinical update. Article Title
Negative Sentiment: Director Atul Pande sold 6,000 shares in a pre-arranged transaction, which may slightly temper sentiment even though it was disclosed under a Rule 10b5-1 plan. Article Title

Analysts Set New Price Targets

Several equities analysts have issued reports on IMVT shares. Sanford C. Bernstein started coverage on Immunovant in a report on Friday, March 20th. They set a "market perform" rating and a $28.00 price objective on the stock. HC Wainwright reissued a "buy" rating and set a $35.00 price target on shares of Immunovant in a report on Tuesday, February 10th. Bank of America reissued a "buy" rating on shares of Immunovant in a report on Thursday. The Goldman Sachs Group raised their price target on Immunovant from $29.00 to $32.00 and gave the stock a "neutral" rating in a report on Wednesday, April 15th. Finally, Guggenheim raised their price target on Immunovant from $41.00 to $44.00 and gave the stock a "buy" rating in a report on Monday, February 9th. Six investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $32.44.

Check Out Our Latest Research Report on IMVT

Hedge Funds Weigh In On Immunovant

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Geneos Wealth Management Inc. purchased a new position in shares of Immunovant during the fourth quarter worth about $25,000. Strs Ohio purchased a new position in shares of Immunovant during the first quarter worth about $27,000. Aster Capital Management DIFC Ltd purchased a new position in shares of Immunovant during the third quarter worth about $33,000. PNC Financial Services Group Inc. lifted its position in Immunovant by 138.9% in the third quarter. PNC Financial Services Group Inc. now owns 2,831 shares of the company's stock valued at $46,000 after purchasing an additional 1,646 shares during the period. Finally, Quarry LP lifted its position in Immunovant by 94.9% in the fourth quarter. Quarry LP now owns 3,000 shares of the company's stock valued at $76,000 after purchasing an additional 1,461 shares during the period. Hedge funds and other institutional investors own 47.08% of the company's stock.

Immunovant Company Profile

(Get Free Report)

Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant's approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.

The company's lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG.